STOCK TITAN

SQZ BIOTECHNOLOGIES CO - $SQZB STOCK NEWS

Welcome to our dedicated page for SQZ BIOTECHNOLOGIES CO news (Ticker: $SQZB), a resource for investors and traders seeking the latest updates and insights on SQZ BIOTECHNOLOGIES CO stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect SQZ BIOTECHNOLOGIES CO's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of SQZ BIOTECHNOLOGIES CO's position in the market.

Rhea-AI Summary
SQZ Biotechnologies (SQZB) announced shareholder approval for asset sale and liquidation. Over 98% of votes favored the sale and dissolution, with closing on March 4, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
21.62%
Tags
none
-
Rhea-AI Summary
SQZ Biotechnologies Company (SQZB) reports third quarter 2023 financial results and portfolio updates with positive clinical trial data for its AAC and eAPC platforms in oncology. The company also reduced its workforce by 80% to lower operating expenses while pursuing strategic alternatives. Financial highlights include a net loss of $23.6 million and cash and cash equivalents of $10.2 million as of September 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
SQZ Biotechnologies presented clinical data for three programs focused on the treatment of Human Papillomavirus 16 positive (HB16+) driven cancers. The SQZ AAC Phase 1 trial observed a best overall response of stable disease or better in 60% of treated patients. The SQZ eAPC Phase 1/2 trial observed stable disease in 40% of treated patients. The SQZ APC Phase 1 trial increased overall survival in a subset of patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.46%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.59%
Tags
none
SQZ BIOTECHNOLOGIES CO

OTC:SQZB

SQZB Rankings

SQZB Stock Data

1.47M
25.86M
2.1%
23.09%
2.75%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
Watertown

About SQZB

spun out of mit, sqz biotechnologies is developing the next generation of cell therapies, using its propriety technology to harness the power of the patient's immune system to combat disease. sqz: empower cells to change lives.